Ozempic, Wegovy, other GLP-1RA drugs not linked to increased pancreatic cancer risk, study finds
Posted:
New research has concluded that drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
From detecting TB, cancer, and heart attacks to diagnosing patients with strokes and diabetes, Artificial Intelligence (AI) is redefining the healthcare system across the world. Currently, more than 90% of hospitals and healthcare systems have implemented an AI or automation strategy,…